VF in the News

US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica

The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. Kevzara has been approved as the first and only biologic indicated for PMR adult patients who did not respond to corticosteroids or who cannot tolerate corticosteroid taper. Developed using…...

Read more

Amgen Successfully Completes Acquisition of ChemoCentryx

TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat…...

Read more

Mom Climbs Highest Mountain in Africa in Memory of Her Extraordinary Daughter

Update: Jo has made it to the top of Mt. Kilimanjaro! The climb was by far the hardest thing she’s ever had to face other than losing her daughter, Amy, to vasculitis. “They call it ‘The Roof of Africa’ but I call it almost to heaven! It’s the closest I’ll…...

Read more

2022 V-RED Winners

There’s something unique about the Vasculitis Foundation’s (VF’s) 2022 Recognizing Excellence in Diagnostics (V-RED) award program: We have two winners who tied for first place and two winners who received honorable mentions. Now in its ninth year, the V-RED award program calls on patients worldwide to nominate a medical professional…...

Read more